3 years ago

Low-Dose Methotrexate for the Prevention of Atherosclerotic Events.

Paul M Ridker, Brendan M. Everett, Aruna Pradhan, Jean G. MacFadyen, Daniel H. Solomon, Elaine Zaharris, Virak Mam, Ahmed Hasan, Yves Rosenberg, Erin Iturriaga, Milan Gupta, Michelle Tsigoulis, Subodh Verma, Michael Clearfield, Peter Libby, Samuel Z. Goldhaber, Roger Seagle, Cyril Ofori, Mohammad Saklayen, Samuel Butman, Narendra Singh, Michel Le May, Olivier Bertrand, James Johnston, Nina P. Paynter, Robert J. Glynn
Inflammation is causally related to atherothrombosis. Treatment with canakinumab, a monoclonal antibody that inhibits inflammation by neutralizing interleukin-1β, resulted in a lower rate of cardiovascular events than placebo in a previous randomized trial. We sought to determine whether an alternative approach to inflammation inhibition with low-dose methotrexate might provide similar benefit.

Publisher URL: http://doi.org/10.1056/NEJMoa1809798

DOI: 10.1056/NEJMoa1809798

You might also like
Discover & Discuss Important Research

Keeping up-to-date with research can feel impossible, with papers being published faster than you'll ever be able to read them. That's where Researcher comes in: we're simplifying discovery and making important discussions happen. With over 19,000 sources, including peer-reviewed journals, preprints, blogs, universities, podcasts and Live events across 10 research areas, you'll never miss what's important to you. It's like social media, but better. Oh, and we should mention - it's free.

  • Download from Google Play
  • Download from App Store
  • Download from AppInChina

Researcher displays publicly available abstracts and doesn’t host any full article content. If the content is open access, we will direct clicks from the abstracts to the publisher website and display the PDF copy on our platform. Clicks to view the full text will be directed to the publisher website, where only users with subscriptions or access through their institution are able to view the full article.